Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet

Zura Bio Ltd

Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.
Trial enrolls ~80 adults, randomized 1:1 tibulizumab versus placebo for 24 weeks, then 28-week open-label extension.
Primary endpoint is change in modified Rodnan Skin Score at Week 24; topline results expected first half 2027.
No clinical efficacy or safety data will be presented; poster covers rationale and study design only.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-023806
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2026-03-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.568056+00:00
generated_at: 2026-05-15T19:52:42.057884+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-023806
json_url: https://secwatch.observer/filing/0001104659-26-023806.json
markdown_url: https://secwatch.observer/filing/0001104659-26-023806.md
text_url: https://secwatch.observer/filing/0001104659-26-023806.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/0001104659-26-023806-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/tm268054d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-023806

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.